Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0VN7G
|
|||
| Former ID |
DNC005009
|
|||
| Drug Name |
Hexahydro-pyrrolizin-(3E)-ylideneamine
|
|||
| Synonyms |
Hexahydro-pyrrolizin-(3E)-ylideneamine; CHEMBL185535; 765304-80-1; 3h-pyrrolizin-3-imine,hexahydro-; BDBM50150910
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C7H12N2
|
|||
| Canonical SMILES |
C1CC2CCC(=N)N2C1
|
|||
| InChI |
1S/C7H12N2/c8-7-4-3-6-2-1-5-9(6)7/h6,8H,1-5H2
|
|||
| InChIKey |
IGTGCXXJCCYMRS-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nitric-oxide synthase brain (NOS1) | Target Info | Inhibitor | [1] |
| BioCyc | Citrulline-nitric oxide cycle | |||
| KEGG Pathway | Arginine and proline metabolism | |||
| Metabolic pathways | ||||
| Calcium signaling pathway | ||||
| Phagosome | ||||
| Circadian entrainment | ||||
| Long-term depression | ||||
| Salivary secretion | ||||
| Alzheimer's disease | ||||
| Amyotrophic lateral sclerosis (ALS) | ||||
| NetPath Pathway | EGFR1 Signaling Pathway | |||
| Panther Pathway | CCKR signaling map ST | |||
| Pathwhiz Pathway | Arginine and Proline Metabolism | |||
| Reactome | ROS production in response to bacteria | |||
| Nitric oxide stimulates guanylate cyclase | ||||
| WikiPathways | Monoamine Transport | |||
| Myometrial Relaxation and Contraction Pathways | ||||
| Amyotrophic lateral sclerosis (ALS) | ||||
| Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | ||||
| Spinal Cord Injury | ||||
| Alzheimers Disease | ||||
| Effects of Nitric Oxide | ||||
| Serotonin Transporter Activity | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.